FANJ
VRTX icon

Financial Architects (New Jersey)’s Vertex Pharmaceuticals VRTX Stock Holding History

Financial Architects (New Jersey)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-200
Closed -$39K – 1512
2018
Q3 		$39K Buy
+200
New +$35.6K 0.01% 713
2018
Q1 		– Sell
-700
Closed -$105K – 1602
2017
Q4 		$105K Buy
+700
New +$104K 0.02% 475

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Financial Architects (New Jersey)'s VRTX Position: Q2 2020 in Review

Financial Architects (New Jersey) sold out of Vertex Pharmaceuticals (VRTX) in Q2 2020, closing a stake of 87 shares — an estimated $21K sold.

Financial Architects (New Jersey) first reported a position in VRTX in Q3 2014 and held it in 18 quarters. The position peaked at $44K in Q2 2018. 964 funds tracked by Wall St. Rank hold VRTX as of Q2 2020.

  • Financial Architects (New Jersey) reported no remaining Vertex Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 87 Vertex Pharmaceuticals shares in Q2 2020, an estimated $21K.
  • Financial Architects (New Jersey) first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 18 quarters.
  • Financial Architects (New Jersey)'s Vertex Pharmaceuticals position peaked at $44K in Q2 2018.
  • 964 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2020.

Based on Financial Architects (New Jersey)'s 13F filing for Q2 2020, filed 11 Aug 2020.